Frederike J. Bemelman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Frederike J. Bemelman has a total of 217 co-authors. Here are the top co-authors by number of shared publications:
- Luuk Hilbrands
Department of Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands
9 shared publications - Aiko P. J. de Vries
Leiden Transplant Center, Leiden University Medical Center, Leiden, the Netherlands
8 shared publications - Ester B. M. Remmerswaal
Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
8 shared publications - Jesper Kers
Systems Pathology Research Group, Department of Pathology, Leiden Transplant Center, Leiden University Medical Center, Leiden, The Netherlands
7 shared publications - Stephan J. Sanders
Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
7 shared publications - Sandrine Florquin
Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
6 shared publications
Latest Publications
- Open Access
Continuous Diagnostic Indices from BanffNET Automated Lesion Scores for Kidney Transplant Pathology: Development and Evaluation of a Diagnostic Prediction Model
Background: Histopathological diagnoses in kidney transplant biopsies, as described by the Banff classification, suffer from substantial inter-observer variability and misinterpretation, making them prone to diagnostic errors. Continuous indices based on BanffNET automated lesion scores are proposed to quantify the continuous phenotypic spectrum of kidney transplant biopsies, complementary to pathologist assessment of biopsies. Methods: The BanffNET model was used to obtain continuous lesion scoring for a training cohort of 2544 biopsies, a large validation cohort of 3863 biopsies, and a multi-reader cohort of 36 biopsies scored by 67 pathologists. A penalized regression approach was used to condense 17 automated lesion scores into four indices, representing the most important dimensions of graft injury: a TCMR/TI Index, an AMR/MVI Index, an Activity Index and a Chronicity Index. The BanffNET Indices were evaluated against Banff diagnoses and histological indices in the training cohort and validation cohort. Since pathologist-assigned Banff lesions and diagnoses suffer from inter-observer variability, associations were also assessed with diagnoses in a multi-reader study, with time to kidney graft failure in the training and validation cohort and with biopsy-based molecular signatures in the validation cohort. Results: The BanffNET TCMR/TI Index, AMR/MVI Index and Activity Index showed excellent discrimination of Banff TCMR, Banff MVI and Banff Any Diagnosis respectively, with validation AUCs ranging from 0.80 to 0.92. In addition, the BanffNET Indices explained large amounts of variability in multi-observer reference standards, time to graft failure and molecular biopsy-based diagnostics. In the large majority of cases, variability explained by BanffNET Indices matched or exceeded the variability explained by pathologist-assigned diagnoses and histological indices. Conclusions: BanffNET Indices are reproducible descriptors of whole slide images that could complement and augment kidney transplant biopsy evaluation by pathologists. Associations of BanffNET Indices with multi-observer diagnoses and related outcomes suggest that they capture additional information on tissue injury type and severity on top of pathologist-assigned Banff diagnoses and histological indices.
Open AccessContinuous Diagnostic Indices from BanffNET Automated Lesion Scores for Kidney Transplant Pathology: Development and Evaluation of a Diagnostic Prediction Model
Background: Histopathological diagnoses in kidney transplant biopsies, as described by the Banff classification, suffer from substantial inter-observer variability and misinterpretation, making them prone to diagnostic errors. Continuous indices based on BanffNET automated lesion scores are proposed to quantify the continuous phenotypic spectrum of kidney transplant biopsies, complementary to pathologist assessment of biopsies. Methods: The BanffNET model was used to obtain continuous lesion scoring for a training cohort of 2544 biopsies, a large validation cohort of 3863 biopsies, and a multi-reader cohort of 36 biopsies scored by 67 pathologists. A penalized regression approach was used to condense 17 automated lesion scores into four indices, representing the most important dimensions of graft injury: a TCMR/TI Index, an AMR/MVI Index, an Activity Index and a Chronicity Index. The BanffNET Indices were evaluated against Banff diagnoses and histological indices in the training cohort and validation cohort. Since pathologist-assigned Banff lesions and diagnoses suffer from inter-observer variability, associations were also assessed with diagnoses in a multi-reader study, with time to kidney graft failure in the training and validation cohort and with biopsy-based molecular signatures in the validation cohort. Results: The BanffNET TCMR/TI Index, AMR/MVI Index and Activity Index showed excellent discrimination of Banff TCMR, Banff MVI and Banff Any Diagnosis respectively, with validation AUCs ranging from 0.80 to 0.92. In addition, the BanffNET Indices explained large amounts of variability in multi-observer reference standards, time to graft failure and molecular biopsy-based diagnostics. In the large majority of cases, variability explained by BanffNET Indices matched or exceeded the variability explained by pathologist-assigned diagnoses and histological indices. Conclusions: BanffNET Indices are reproducible descriptors of whole slide images that could complement and augment kidney transplant biopsy evaluation by pathologists. Associations of BanffNET Indices with multi-observer diagnoses and related outcomes suggest that they capture additional information on tissue injury type and severity on top of pathologist-assigned Banff diagnoses and histological indices.
- 11 September 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Plasma versus Whole Blood Tacrolimus Concentration and Outcomes after Kidney Transplantation
Key Points: Repeated measurements of plasma tacrolimus concentrations were obtained retrospectively from 295 kidney transplant recipients. Plasma tacrolimus concentration was negatively associated with later eGFR, whereas whole blood concentration was not. Plasma tacrolimus concentration was associated with arteriolar hyalinosis in protocol biopsies, whereas whole blood concentration was not. Background: Tacrolimus is the cornerstone of immunosuppressive treatment after kidney transplantation. Its application requires therapeutic drug monitoring, which is routinely performed by assessment of whole blood tacrolimus concentrations (WBTC) that largely comprises a pharmacologically inactive fraction. Monitoring tacrolimus exposure using the plasma tacrolimus concentration (PTC) may better reflect the pharmacologic active fraction. We hypothesized that PTC better reflects effectivity and toxicity than WBTC. Methods: The Amsterdam, LEiden, GROningen trial randomized 295 kidney transplant recipients (KTR) to standard triple immunosuppression, lower tacrolimus exposure, or withdrawal of prednisolone. PTC was measured using liquid chromatography–tandem mass spectrometry. Associations between tacrolimus concentrations and eGFR were analyzed using linear regression, with bootstrap resampling used to compare PTC and WBTC. Associations with biopsy results and rejection were evaluated using logistic regression, and infection risk was assessed with joint modeling. Results: The mean age was 56.5±13.2 years, and 95 (32%) were female. The mean PTC during the first month post-transplantation (0.31±0.17 ng/ml) was negatively associated with eGFR at 4 weeks (st. β =−0.17 [−0.29 to −0.05], P = 0.006), whereas mean WBTC was not (st. β =0.09 [−0.03 to 0.22], P = 0.15), and the difference between these associations was statistically significant ( P = 0.004). Late mean PTC (6.5–24 months; 0.15±0.07 ng/ml) was negatively associated with eGFR at 2 years (st. β =−0.19 [−0.35 to −0.03], P = 0.02), whereas mean WBTC was not (st. β =0.04 [−0.13 to 0.20], P = 0.66), and this difference was also statistically significant ( P = 0.02). At 2 years, 10 (14%) of the 71 protocol biopsies showed moderate-to-severe arteriolar hyalinosis. Although in a limited number of events, late mean PTC was significantly associated with a risk of arteriolar hyalinosis (odds ratio=1.96 [1.07–3.80], P = 0.03), WBTC was not (odds ratio=1.65 [0.83–3.53], P = 0.17). Neither PTC nor WBTC was significantly associated with a risk of infection in univariable analysis. Twenty-two KTR (7%) experienced biopsy-proven rejection; neither PTC nor WBTC was associated with rejection. Conclusion: Larger studies are needed to determine whether late PTC is a better marker than WBTC to detect potential tacrolimus-related nephrotoxicity in KTR. Clinical Trial registry name and registration number: NCT01560572.
- 11 September 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Plasma versus Whole Blood Tacrolimus Concentration and Outcomes after Kidney Transplantation
Key Points: Repeated measurements of plasma tacrolimus concentrations were obtained retrospectively from 295 kidney transplant recipients. Plasma tacrolimus concentration was negatively associated with later eGFR, whereas whole blood concentration was not. Plasma tacrolimus concentration was associated with arteriolar hyalinosis in protocol biopsies, whereas whole blood concentration was not. Background: Tacrolimus is the cornerstone of immunosuppressive treatment after kidney transplantation. Its application requires therapeutic drug monitoring, which is routinely performed by assessment of whole blood tacrolimus concentrations (WBTC) that largely comprises a pharmacologically inactive fraction. Monitoring tacrolimus exposure using the plasma tacrolimus concentration (PTC) may better reflect the pharmacologic active fraction. We hypothesized that PTC better reflects effectivity and toxicity than WBTC. Methods: The Amsterdam, LEiden, GROningen trial randomized 295 kidney transplant recipients (KTR) to standard triple immunosuppression, lower tacrolimus exposure, or withdrawal of prednisolone. PTC was measured using liquid chromatography–tandem mass spectrometry. Associations between tacrolimus concentrations and eGFR were analyzed using linear regression, with bootstrap resampling used to compare PTC and WBTC. Associations with biopsy results and rejection were evaluated using logistic regression, and infection risk was assessed with joint modeling. Results: The mean age was 56.5±13.2 years, and 95 (32%) were female. The mean PTC during the first month post-transplantation (0.31±0.17 ng/ml) was negatively associated with eGFR at 4 weeks (st. β =−0.17 [−0.29 to −0.05], P = 0.006), whereas mean WBTC was not (st. β =0.09 [−0.03 to 0.22], P = 0.15), and the difference between these associations was statistically significant ( P = 0.004). Late mean PTC (6.5–24 months; 0.15±0.07 ng/ml) was negatively associated with eGFR at 2 years (st. β =−0.19 [−0.35 to −0.03], P = 0.02), whereas mean WBTC was not (st. β =0.04 [−0.13 to 0.20], P = 0.66), and this difference was also statistically significant ( P = 0.02). At 2 years, 10 (14%) of the 71 protocol biopsies showed moderate-to-severe arteriolar hyalinosis. Although in a limited number of events, late mean PTC was significantly associated with a risk of arteriolar hyalinosis (odds ratio=1.96 [1.07–3.80], P = 0.03), WBTC was not (odds ratio=1.65 [0.83–3.53], P = 0.17). Neither PTC nor WBTC was significantly associated with a risk of infection in univariable analysis. Twenty-two KTR (7%) experienced biopsy-proven rejection; neither PTC nor WBTC was associated with rejection. Conclusion: Larger studies are needed to determine whether late PTC is a better marker than WBTC to detect potential tacrolimus-related nephrotoxicity in KTR. Clinical Trial registry name and registration number: NCT01560572.
- Open Access
- 19 March 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (7) , 1633-1647
Early Lymphoid Aggregates in Protocol Kidney Allograft Biopsies
Background: The presence of lymphoid tissues and their impact on long-term kidney graft outcome remains unclear. This study investigates the occurrence, molecular and phenotypic characteristics of lymphoid aggregates (LA) in protocol biopsies of clinically stable kidney transplant recipients, and their correlation with long-term clinical outcome. Methods: We retrospectively analyzed 414 protocol biopsies from a multicenter cohort of 278 stable kidney transplant recipients taken at either 6-, 12- or 24-months post-transplant. On a subset of 16 biopsies at 6 months post-transplant, mRNA gene expression analysis was performed using Nanostring B-HOT panel alongside phenotypic analysis with immunostaining for developmental staging of LA. Finally, the presence of LA was correlated to various clinical kidney allograft outcomes. Results: Stage I LA were characterized by upregulation of genes linked to immune regulation (LAG3, CTLA4, FOXP3), T-cell signaling, and chemotaxis pathways, with enrichment of regulatory T cells (Tregs), memory T cells, T follicular helper cells (Tfh), and dendritic cells. Immunohistochemistry confirmed higher numbers of FOXP3+ Tregs and dendritic cells in stage I LA, while high endothelial venules were absent. Over follow-up, participants with stage I LA showed slightly higher eGFR values and a trend toward better graft survival compared with those without LA or with stage II LA, although most differences did not reach statistical significance. Conclusions: In stable kidney transplant recipients, stage I LA displayed molecular and phenotypic features consistent with a regulated immune environment. The molecular and immunohistochemical analysis of stage I LA suggests a more regulatory molecular phenotype and composition, which may contribute to better long-term graft survival observed in this cohort of functionally stable transplant recipients. Observed trends toward more favorable outcomes suggest that early LA may not be deleterious and could represent local immune regulation, though larger prospective studies are needed to confirm these findings.
- 19 March 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (7) , 1633-1647
Open AccessEarly Lymphoid Aggregates in Protocol Kidney Allograft Biopsies
Background: The presence of lymphoid tissues and their impact on long-term kidney graft outcome remains unclear. This study investigates the occurrence, molecular and phenotypic characteristics of lymphoid aggregates (LA) in protocol biopsies of clinically stable kidney transplant recipients, and their correlation with long-term clinical outcome. Methods: We retrospectively analyzed 414 protocol biopsies from a multicenter cohort of 278 stable kidney transplant recipients taken at either 6-, 12- or 24-months post-transplant. On a subset of 16 biopsies at 6 months post-transplant, mRNA gene expression analysis was performed using Nanostring B-HOT panel alongside phenotypic analysis with immunostaining for developmental staging of LA. Finally, the presence of LA was correlated to various clinical kidney allograft outcomes. Results: Stage I LA were characterized by upregulation of genes linked to immune regulation (LAG3, CTLA4, FOXP3), T-cell signaling, and chemotaxis pathways, with enrichment of regulatory T cells (Tregs), memory T cells, T follicular helper cells (Tfh), and dendritic cells. Immunohistochemistry confirmed higher numbers of FOXP3+ Tregs and dendritic cells in stage I LA, while high endothelial venules were absent. Over follow-up, participants with stage I LA showed slightly higher eGFR values and a trend toward better graft survival compared with those without LA or with stage II LA, although most differences did not reach statistical significance. Conclusions: In stable kidney transplant recipients, stage I LA displayed molecular and phenotypic features consistent with a regulated immune environment. The molecular and immunohistochemical analysis of stage I LA suggests a more regulatory molecular phenotype and composition, which may contribute to better long-term graft survival observed in this cohort of functionally stable transplant recipients. Observed trends toward more favorable outcomes suggest that early LA may not be deleterious and could represent local immune regulation, though larger prospective studies are needed to confirm these findings.
- Open Access
- 3 March 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (3) , e0336320
Class switching toward IgG4 six months after primary mRNA-based COVID-19 vaccination in kidney patients
Background: Class switching toward spike (S)-binding IgG4 antibodies after mRNA-based COVID-19 vaccination has been observed, an antibody subclass with strong neutralizing but limited effector activity. While this has been reported in healthy individuals, subclass dynamics in immunocompromised kidney patients are unclear. We assessed IgG subclass patterns and S-specific B-cell phenotypes up to 6 months after a two-dose mRNA-1273 vaccination schedule in kidney transplant recipients (KTRs), dialysis patients, and patients with chronic kidney disease (CKD). Methods: In this exploratory study, KTRs (n = 11), dialysis patients (n = 5), CKD stage G4–5 patients (eGFR < 30 ml/min/1.73m2, n = 5), and controls without known kidney disease (eGFR > 45 ml/min/1.73m2, n = 8) received two mRNA-1273 doses 28 days apart. Blood was collected pre-vaccination (V1), and at 28 days (V3) and 6 months (V4) after the second dose. S1-specific IgG antibodies were measured by a validated fluorescent bead-based multiplex-immunoassay, and participants seronegative at V1 and seropositive at V3 were included. B cells were phenotyped by flow cytometry. Results: Five of 11 KTRs had no detectable S-binding B cells, whereas all other groups mounted responses. Across responders, the frequency of S-binding B cells increased from V1 (median 0.08%) to 0.49% at V3 and to 0.84% at V4 (both p < 0.0001). S-binding B cells mainly comprised IgG⁺ plasmablasts. The IgG4:IgG1 log-ratio increased significantly from V3 to V4 (p < 0.001), indicating a relative shift toward IgG4; absolute frequencies were comparable across the groups. Conclusions: Approximately half of KTRs lacked detectable S-binding B cells after two mRNA-1273 doses, despite antibody formation. Among responders, S-binding B cells persisted up to 6 months after vaccination with a relative shift toward IgG4, a pattern also observed in dialysis patients, CKD patients and controls. The clinical significance of this subclass skewing requires confirmation in larger cohorts with functional antibody readouts.
- 3 March 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (3) , e0336320
Open AccessClass switching toward IgG4 six months after primary mRNA-based COVID-19 vaccination in kidney patients
Background: Class switching toward spike (S)-binding IgG4 antibodies after mRNA-based COVID-19 vaccination has been observed, an antibody subclass with strong neutralizing but limited effector activity. While this has been reported in healthy individuals, subclass dynamics in immunocompromised kidney patients are unclear. We assessed IgG subclass patterns and S-specific B-cell phenotypes up to 6 months after a two-dose mRNA-1273 vaccination schedule in kidney transplant recipients (KTRs), dialysis patients, and patients with chronic kidney disease (CKD). Methods: In this exploratory study, KTRs (n = 11), dialysis patients (n = 5), CKD stage G4–5 patients (eGFR < 30 ml/min/1.73m2, n = 5), and controls without known kidney disease (eGFR > 45 ml/min/1.73m2, n = 8) received two mRNA-1273 doses 28 days apart. Blood was collected pre-vaccination (V1), and at 28 days (V3) and 6 months (V4) after the second dose. S1-specific IgG antibodies were measured by a validated fluorescent bead-based multiplex-immunoassay, and participants seronegative at V1 and seropositive at V3 were included. B cells were phenotyped by flow cytometry. Results: Five of 11 KTRs had no detectable S-binding B cells, whereas all other groups mounted responses. Across responders, the frequency of S-binding B cells increased from V1 (median 0.08%) to 0.49% at V3 and to 0.84% at V4 (both p < 0.0001). S-binding B cells mainly comprised IgG⁺ plasmablasts. The IgG4:IgG1 log-ratio increased significantly from V3 to V4 (p < 0.001), indicating a relative shift toward IgG4; absolute frequencies were comparable across the groups. Conclusions: Approximately half of KTRs lacked detectable S-binding B cells after two mRNA-1273 doses, despite antibody formation. Among responders, S-binding B cells persisted up to 6 months after vaccination with a relative shift toward IgG4, a pattern also observed in dialysis patients, CKD patients and controls. The clinical significance of this subclass skewing requires confirmation in larger cohorts with functional antibody readouts.
- Open Access
Repeated histological diagnoses and kidney graft failure: an observational cohort study
A bstract: Background: Banff histological diagnoses do not capture how a graft’s injury has evolved over time. Repeated injury is common, but the consequences of repeated histological injury are currently not known, especially when observed in the absence of clinical signs. Methods: In a single-center observational cohort of 1818 kidney transplantations performed between 2004 and 2021, with 5218 post-transplant biopsies of which 82% were pre-planned protocol biopsies, transitions between six Banff histological diagnoses were described as recurrent events, with landmark Aalen-Johansen estimates and unadjusted Andersen-Gill rate ratios. A multistate model, with states for a first and a second diagnosis of rejection-related injury (RRI, comprising TCMR, AMR and MVI DSA-/C4d- ), estimated cause-specific hazards of death-censored graft failure, in all biopsies and in protocol biopsies only. Follow-up ran from day 90 to five years after transplantation. Results: Each diagnosis was more frequent after an earlier episode of the same diagnosis, and several diagnoses also made a different diagnosis more or less frequent: TCMR was more frequent after AMR, MVI DSA-/C4d- and BKPyVAN, and AMR less frequent after MVI DSA-/C4d- . The hazard of graft failure was increased after a first RRI diagnosis (HR 2.18, 95% CI 1.35–3.51) and substantially further after a second (HR 9.31, 95% CI 5.84–14.85). The association persisted when both diagnoses were made on protocol biopsy, in the absence of clinical signs (HR 1.76, 95% CI 1.09–2.84 and HR 2.58, 95% CI 1.31–5.08), although the difference between a second and a first diagnosis was not statistically significant. Conclusions: A prior Banff diagnosis strongly predicts that same diagnosis recurring, and in several cases also changes the expected incidence of a different diagnosis. A second diagnosis of rejection-related injury identifies a markedly higher-risk graft than a first, independently of baseline risk factors, and subclinical episodes detected on protocol biopsy also mark increased risk. This defines both an unmet therapeutic need and a high-risk population for trial enrichment. K ey learning points: What was known: A Banff diagnosis is rendered from a single biopsy, yet alloimmune injury often persists, recurs or changes over time. Repeated T-cell mediated rejection adds risk of graft failure, but evidence comes almost entirely from indication biopsies. How other diagnoses recur, and whether one predicts another, was largely unknown. This study adds: In 1818 transplants with 5218 biopsies (82% protocol), a prior diagnosis strongly predicted its recurrence and altered the incidence of others. A second rejection-related episode carried a significantly higher hazard of death-censored graft failure than a first (9.31 versus 2.18). Subclinical protocol-biopsy episodes also carried risk (2.58 versus 1.76). Potential impact: A first episode marks a graft at elevated risk, not a resolved problem. Biopsies are best read alongside the graft’s diagnostic history. Protocol biopsies detect prognostically relevant injury in apparently well recipients. Recipients with a second episode form a high-risk group suited to trials of more durable immune modulation.
Open AccessRepeated histological diagnoses and kidney graft failure: an observational cohort study
A bstract: Background: Banff histological diagnoses do not capture how a graft’s injury has evolved over time. Repeated injury is common, but the consequences of repeated histological injury are currently not known, especially when observed in the absence of clinical signs. Methods: In a single-center observational cohort of 1818 kidney transplantations performed between 2004 and 2021, with 5218 post-transplant biopsies of which 82% were pre-planned protocol biopsies, transitions between six Banff histological diagnoses were described as recurrent events, with landmark Aalen-Johansen estimates and unadjusted Andersen-Gill rate ratios. A multistate model, with states for a first and a second diagnosis of rejection-related injury (RRI, comprising TCMR, AMR and MVI DSA-/C4d- ), estimated cause-specific hazards of death-censored graft failure, in all biopsies and in protocol biopsies only. Follow-up ran from day 90 to five years after transplantation. Results: Each diagnosis was more frequent after an earlier episode of the same diagnosis, and several diagnoses also made a different diagnosis more or less frequent: TCMR was more frequent after AMR, MVI DSA-/C4d- and BKPyVAN, and AMR less frequent after MVI DSA-/C4d- . The hazard of graft failure was increased after a first RRI diagnosis (HR 2.18, 95% CI 1.35–3.51) and substantially further after a second (HR 9.31, 95% CI 5.84–14.85). The association persisted when both diagnoses were made on protocol biopsy, in the absence of clinical signs (HR 1.76, 95% CI 1.09–2.84 and HR 2.58, 95% CI 1.31–5.08), although the difference between a second and a first diagnosis was not statistically significant. Conclusions: A prior Banff diagnosis strongly predicts that same diagnosis recurring, and in several cases also changes the expected incidence of a different diagnosis. A second diagnosis of rejection-related injury identifies a markedly higher-risk graft than a first, independently of baseline risk factors, and subclinical episodes detected on protocol biopsy also mark increased risk. This defines both an unmet therapeutic need and a high-risk population for trial enrichment. K ey learning points: What was known: A Banff diagnosis is rendered from a single biopsy, yet alloimmune injury often persists, recurs or changes over time. Repeated T-cell mediated rejection adds risk of graft failure, but evidence comes almost entirely from indication biopsies. How other diagnoses recur, and whether one predicts another, was largely unknown. This study adds: In 1818 transplants with 5218 biopsies (82% protocol), a prior diagnosis strongly predicted its recurrence and altered the incidence of others. A second rejection-related episode carried a significantly higher hazard of death-censored graft failure than a first (9.31 versus 2.18). Subclinical protocol-biopsy episodes also carried risk (2.58 versus 1.76). Potential impact: A first episode marks a graft at elevated risk, not a resolved problem. Biopsies are best read alongside the graft’s diagnostic history. Protocol biopsies detect prognostically relevant injury in apparently well recipients. Recipients with a second episode form a high-risk group suited to trials of more durable immune modulation.
- Open Access
- 4 February 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Collapsing FSGS in a kidney transplant with a single APOL1 risk variant: a case report
Apolipoprotein L1 (APOL1) genetic risk variants substantially increase the risk of chronic kidney disease and kidney failure among individuals of recent Af
- 4 February 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Open AccessCollapsing FSGS in a kidney transplant with a single APOL1 risk variant: a case report
Apolipoprotein L1 (APOL1) genetic risk variants substantially increase the risk of chronic kidney disease and kidney failure among individuals of recent Af
- Open Access
- 10 January 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (5) , 1087-1099
Comparable outcomes for old, older, and very old deceased donors in old kidney transplant recipients
- 10 January 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (5) , 1087-1099
Open AccessComparable outcomes for old, older, and very old deceased donors in old kidney transplant recipients
- Open Access
- 7 November 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (4) , 814-824
Immunosuppression in Older Kidney Transplant Recipients
Key Points: Low-dose tacrolimus, everolimus, and prednisolone did not result in a higher rate of successful transplantation in older kidney transplant recipients. Low-dose tacrolimus, everolimus, and prednisolone did not result in better kidney function or fewer infections in older kidney transplant recipients. Background: We hypothesized that older kidney transplant recipients receiving low-dose tacrolimus, everolimus, and prednisolone (TEP) have better outcomes than patients receiving standard-dose tacrolimus, mycophenolate mofetil, and prednisolone (TMP). Methods: The OPTIMIZE study was a randomized clinical trial in kidney transplant recipients age ≥65 years. Patients receiving a kidney from a deceased donor older than 65 years (stratum A) or a kidney from a deceased donor younger than 65 years or a living donor (stratum B) were included. Patients were randomized to TEP or TMP groups. Tacrolimus target trough levels in the TEP group were 5–7 ng/ml until 3 months, 2–4 ng/ml from 3 to 6 months, and 1.5–4 ng/ml from 6 months onwards. Tacrolimus target trough levels in the TMP group were 8–12, 6–10, and 5–8 ng/ml. Everolimus target trough levels were 3–6 µ g/L. The primary end point of successful transplantation was defined as being alive with a functioning graft with an eGFR above a predefined threshold at 2 years after transplantation. Predefined eGFR thresholds were 30 (stratum A) or 45 ml/min per 1.73 m 2 (stratum B). Results: A total of 379 patients were randomized, of whom 198 were in stratum A (TEP 97, TMP 101) and 181 in stratum B (TEP 90, TMP 91). The median trough levels for everolimus and tacrolimus were within the target range throughout the study. There was no statistically significant difference in successful transplantation at 2 years between the groups (TEP 94 [50%], TMP 110 [57%]; difference 7% [95% confidence interval, −17 to 3] P = 0.91). Regarding the predefined secondary outcomes, patient survival (TEP 167 [89%], TMP 171 [89%]; P = 0.95) and graft survival (TEP 155 [83%], TMP 162 [84%]; P = 0.65) did not differ significantly. Within strata A and B, there were no significant differences in the end points. Conclusions: Immunosuppression with low-dose tacrolimus, everolimus, and prednisolone did not result in a higher rate of successful transplantation in de novo older kidney transplant recipients compared with immunosuppression with standard-dose TMP. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT03797196.
- 7 November 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (4) , 814-824
Open AccessImmunosuppression in Older Kidney Transplant Recipients
Key Points: Low-dose tacrolimus, everolimus, and prednisolone did not result in a higher rate of successful transplantation in older kidney transplant recipients. Low-dose tacrolimus, everolimus, and prednisolone did not result in better kidney function or fewer infections in older kidney transplant recipients. Background: We hypothesized that older kidney transplant recipients receiving low-dose tacrolimus, everolimus, and prednisolone (TEP) have better outcomes than patients receiving standard-dose tacrolimus, mycophenolate mofetil, and prednisolone (TMP). Methods: The OPTIMIZE study was a randomized clinical trial in kidney transplant recipients age ≥65 years. Patients receiving a kidney from a deceased donor older than 65 years (stratum A) or a kidney from a deceased donor younger than 65 years or a living donor (stratum B) were included. Patients were randomized to TEP or TMP groups. Tacrolimus target trough levels in the TEP group were 5–7 ng/ml until 3 months, 2–4 ng/ml from 3 to 6 months, and 1.5–4 ng/ml from 6 months onwards. Tacrolimus target trough levels in the TMP group were 8–12, 6–10, and 5–8 ng/ml. Everolimus target trough levels were 3–6 µ g/L. The primary end point of successful transplantation was defined as being alive with a functioning graft with an eGFR above a predefined threshold at 2 years after transplantation. Predefined eGFR thresholds were 30 (stratum A) or 45 ml/min per 1.73 m 2 (stratum B). Results: A total of 379 patients were randomized, of whom 198 were in stratum A (TEP 97, TMP 101) and 181 in stratum B (TEP 90, TMP 91). The median trough levels for everolimus and tacrolimus were within the target range throughout the study. There was no statistically significant difference in successful transplantation at 2 years between the groups (TEP 94 [50%], TMP 110 [57%]; difference 7% [95% confidence interval, −17 to 3] P = 0.91). Regarding the predefined secondary outcomes, patient survival (TEP 167 [89%], TMP 171 [89%]; P = 0.95) and graft survival (TEP 155 [83%], TMP 162 [84%]; P = 0.65) did not differ significantly. Within strata A and B, there were no significant differences in the end points. Conclusions: Immunosuppression with low-dose tacrolimus, everolimus, and prednisolone did not result in a higher rate of successful transplantation in de novo older kidney transplant recipients compared with immunosuppression with standard-dose TMP. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT03797196.
- Open Access
Class switching toward IgG4 six months after primary mRNA-based COVID-19 vaccination in kidney patients
Background: Class switching toward spike (S)-binding IgG4 antibodies after mRNA-based COVID-19 vaccination has been observed, an antibody subclass with strong neutralizing but limited effector activity. While this has been reported in healthy individuals, subclass dynamics in immunocompromised kidney patients are unclear. We assessed IgG subclass patterns and S-specific B-cell phenotypes up to 6 months after a two-dose mRNA-1273 vaccination schedule in kidney transplant recipients (KTRs), dialysis patients, and patients with chronic kidney disease (CKD). Methods: In this exploratory study, KTRs (n=11), dialysis patients (n=5), CKD stage G4–5 patients (eGFR 45 ml/min/1.73m2, n=8) received two mRNA-1273 doses 28 days apart. Blood was collected pre-vaccination (V1), and at 28 days (V3) and 6 months (V4) after the second dose. S1-specific IgG antibodies were measured by a validated fluorescent bead-based multiplex-immunoassay, and participants seronegative at V1 and seropositive at V3 were included. B cells were phenotyped by flow cytometry. Results: Five of 11 KTRs had no detectable S-binding B cells, whereas all other groups mounted responses. Across responders, the frequency of S-binding B cells increased from V1 (median 0.08%) to 0.49% at V3 and to 0.84% at V4 (both p<0.0001). S-binding B cells mainly comprised IgG+ plasmablasts. The IgG4:IgG1 log-ratio increased significantly from V3 to V4 (p<0.001), indicating a relative shift toward IgG4; absolute frequencies were comparable across the groups. Conclusions: Approximately half of KTRs lacked detectable S-binding B cells after two mRNA-1273 doses, despite antibody formation. Among responders, S-binding B cells persisted up to 6 months after vaccination with a relative shift toward IgG4, a pattern also observed in dialysis patients, CKD patients and controls. The clinical significance of this subclass skewing requires confirmation in larger cohorts with functional antibody readouts.
Open AccessClass switching toward IgG4 six months after primary mRNA-based COVID-19 vaccination in kidney patients
Background: Class switching toward spike (S)-binding IgG4 antibodies after mRNA-based COVID-19 vaccination has been observed, an antibody subclass with strong neutralizing but limited effector activity. While this has been reported in healthy individuals, subclass dynamics in immunocompromised kidney patients are unclear. We assessed IgG subclass patterns and S-specific B-cell phenotypes up to 6 months after a two-dose mRNA-1273 vaccination schedule in kidney transplant recipients (KTRs), dialysis patients, and patients with chronic kidney disease (CKD). Methods: In this exploratory study, KTRs (n=11), dialysis patients (n=5), CKD stage G4–5 patients (eGFR 45 ml/min/1.73m2, n=8) received two mRNA-1273 doses 28 days apart. Blood was collected pre-vaccination (V1), and at 28 days (V3) and 6 months (V4) after the second dose. S1-specific IgG antibodies were measured by a validated fluorescent bead-based multiplex-immunoassay, and participants seronegative at V1 and seropositive at V3 were included. B cells were phenotyped by flow cytometry. Results: Five of 11 KTRs had no detectable S-binding B cells, whereas all other groups mounted responses. Across responders, the frequency of S-binding B cells increased from V1 (median 0.08%) to 0.49% at V3 and to 0.84% at V4 (both p<0.0001). S-binding B cells mainly comprised IgG+ plasmablasts. The IgG4:IgG1 log-ratio increased significantly from V3 to V4 (p<0.001), indicating a relative shift toward IgG4; absolute frequencies were comparable across the groups. Conclusions: Approximately half of KTRs lacked detectable S-binding B cells after two mRNA-1273 doses, despite antibody formation. Among responders, S-binding B cells persisted up to 6 months after vaccination with a relative shift toward IgG4, a pattern also observed in dialysis patients, CKD patients and controls. The clinical significance of this subclass skewing requires confirmation in larger cohorts with functional antibody readouts.
- 28 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (9) , 1823-1843
Purinoreceptor P2X7 in Extracellular ATP-Mediated Inflammation through the Spectrum of Kidney Diseases and Kidney Transplantation
Extracellular purines not only play a critical role in maintaining a balanced inflammatory response but may also trigger disproportionate inflammation in various kidney pathologies. Extracellular ATP is the most well-characterized inflammatory purine, which serves as a potent extracellular danger-associated molecular pattern. It signals through the P2 purinoreceptors during both acute and chronic kidney damage. The purinoreceptor P2X7 (P2X7R) has been extensively studied in kidney disease because of its potent ability to enhance inflammation by activating the nucleotide-binding oligomerization domain, leucine rich repeat family pyrin domain containing 3 inflammasome in both immune and parenchymal tubular cells and potential role in immunometabolic reprogramming. We will explore how, following a primary insult to the kidney, disturbance of purinergic balance characterized by extracellular ATP-mediated P2X7R activation exacerbates AKI. Second, we will describe how persistent purinergic disbalance promotes a P2X7R-mediated protracted inflammatory reaction leading to the progression of CKD of different etiologies. Finally, we will also highlight the relevant and emerging role of P2X7R signaling in both antigen-presenting cells and adaptive immune cells to modulate cellular and humoral immune responses in kidney transplantation and hypertension. This review underscores that ATP-P2X7R axis is a key driver of pathologic purinergic signaling, representing a largely unexplored but highly promising clinical target against a wide spectrum of kidney diseases.
- 28 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (9) , 1823-1843
Purinoreceptor P2X7 in Extracellular ATP-Mediated Inflammation through the Spectrum of Kidney Diseases and Kidney Transplantation
Extracellular purines not only play a critical role in maintaining a balanced inflammatory response but may also trigger disproportionate inflammation in various kidney pathologies. Extracellular ATP is the most well-characterized inflammatory purine, which serves as a potent extracellular danger-associated molecular pattern. It signals through the P2 purinoreceptors during both acute and chronic kidney damage. The purinoreceptor P2X7 (P2X7R) has been extensively studied in kidney disease because of its potent ability to enhance inflammation by activating the nucleotide-binding oligomerization domain, leucine rich repeat family pyrin domain containing 3 inflammasome in both immune and parenchymal tubular cells and potential role in immunometabolic reprogramming. We will explore how, following a primary insult to the kidney, disturbance of purinergic balance characterized by extracellular ATP-mediated P2X7R activation exacerbates AKI. Second, we will describe how persistent purinergic disbalance promotes a P2X7R-mediated protracted inflammatory reaction leading to the progression of CKD of different etiologies. Finally, we will also highlight the relevant and emerging role of P2X7R signaling in both antigen-presenting cells and adaptive immune cells to modulate cellular and humoral immune responses in kidney transplantation and hypertension. This review underscores that ATP-P2X7R axis is a key driver of pathologic purinergic signaling, representing a largely unexplored but highly promising clinical target against a wide spectrum of kidney diseases.